Skip to main content
Premium Trial:

Request an Annual Quote

Prostate Cancer AR-V7 Test From Genomic Health, Epic Sciences Gets Final Medicare LCD

NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare Administrative Contractor Palmetto GBA has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test, which was developed and continues to be performed by Epic Sciences.

Palmetto released its draft LCD for the test this March. The final determination recommends limited coverage for use of the test throughout the US to help determine which patients with metastatic castrate-resistant prostate cancer may benefit from continued androgen receptor signaling inhibitor therapy — using drugs like enzalutamide, abiraterone, and apalutamide — and which may be better served by chemotherapy.

The assay uses Epic's "No Cell Left Behind" circulating tumor cell analysis platform to identify AR-V7 positivity in CTC nuclei. Genomic Health partnered with Epic in 2016 to bring the assay to market, and launched it commercially this February.

Studies of the test, including a validation published this June in JAMA Oncology, have shown that detection of AR-V7-positive CTCs indicates that a patient will no longer benefit from commonly prescribed AR inhibitor therapies and will have better survival if switched to chemotherapy.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.